{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:38:10Z","timestamp":1770971890021,"version":"3.50.1"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"DOI":"10.1093\/oncolo\/oyag004","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:39:36Z","timestamp":1769258376000},"source":"Crossref","is-referenced-by-count":0,"title":["Oral relugolix for the treatment of advanced prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-8624","authenticated-orcid":false,"given":"Ronald","family":"Chow","sequence":"first","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3K3,","place":["Canada"]},{"name":"Verspeeten Family Cancer Centre, University of Western Ontario , London, ON N6A 5W9,","place":["Canada"]},{"name":"Centre for Evidence-Based Medicine, University of Oxford , Oxford, OX2 6HT,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Hird","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON M5S 3K3,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[{"name":"Verspeeten Family Cancer Centre, University of Western Ontario , London, ON N6A 5W9,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026021302361696200_oyag004-B1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med."},{"key":"2026021302361696200_oyag004-B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/iju.IJU_497_20","article-title":"HERO trial: a rescue from injectable androgen deprivation therapy","volume":"37","author":"Ranjan","year":"2021","journal-title":"Indian J Urol."},{"key":"2026021302361696200_oyag004-B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-022-","article-title":"Relugolix: a review in advanced prostate cancer","volume":"18","author":"Shirley","year":"2023","journal-title":"Target Oncol."},{"key":"2026021302361696200_oyag004-B4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation."},{"key":"2026021302361696200_oyag004-B5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-","article-title":"The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis","volume":"20","author":"Del Paggio","year":"2019","journal-title":"Lancet Oncol."},{"key":"2026021302361696200_oyag004-B6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","article-title":"The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index","volume":"67","author":"Walsh","year":"2014","journal-title":"J Clin Epidemiol."},{"key":"2026021302361696200_oyag004-B7","year":"2022"},{"key":"2026021302361696200_oyag004-B8","year":"2022"},{"key":"2026021302361696200_oyag004-B9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10637-024-01457-9","article-title":"Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system","volume":"42","author":"Xia","year":"2024","journal-title":"Invest New Drugs."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag004\/66613248\/oyag004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag004\/66613248\/oyag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag004\/66613248\/oyag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:36:25Z","timestamp":1770968185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag004\/8443441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag004","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,28]]},"article-number":"oyag004"}}